<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>SB 352 (Edition 1)</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Times New \(W1\)";}
@font-face
	{font-family:IDAutomationHC39M;
	panose-1:2 0 5 9 0 0 0 2 0 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:12.25pt;
	margin-bottom:.0001pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:23.75pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.MsoLineNumber
	{font-family:"Times New Roman",serif;}
p.LMSBase, li.LMSBase, div.LMSBase
	{mso-style-name:LMSBase;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aArticle, li.aArticle, div.aArticle
	{mso-style-name:aArticle;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aArticleTitle, li.aArticleTitle, div.aArticleTitle
	{mso-style-name:aArticleTitle;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBase, li.aBase, div.aBase
	{mso-style-name:aBase;
	mso-style-link:"aBase Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBillSection, li.aBillSection, div.aBillSection
	{mso-style-name:aBillSection;
	mso-style-link:"aBillSection Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:.75in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBlock1, li.aBlock1, div.aBlock1
	{mso-style-name:aBlock1;
	mso-style-link:"aBlock1 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBlock2, li.aBlock2, div.aBlock2
	{mso-style-name:aBlock2;
	mso-style-link:"aBlock2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.75in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBlock3, li.aBlock3, div.aBlock3
	{mso-style-name:aBlock3;
	mso-style-link:"aBlock3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.25in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBlock4, li.aBlock4, div.aBlock4
	{mso-style-name:aBlock4;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.75in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aBlock5, li.aBlock5, div.aBlock5
	{mso-style-name:aBlock5;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:3.25in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aChapter, li.aChapter, div.aChapter
	{mso-style-name:aChapter;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.aHeading, li.aHeading, div.aHeading
	{mso-style-name:aHeading;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.aLongTitle, li.aLongTitle, div.aLongTitle
	{mso-style-name:aLongTitle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New \(W1\)";
	text-transform:uppercase;}
p.aMargin1, li.aMargin1, div.aMargin1
	{mso-style-name:aMargin1;
	mso-style-link:"aMargin1 Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aMargin2, li.aMargin2, div.aMargin2
	{mso-style-name:aMargin2;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:.75in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aPart, li.aPart, div.aPart
	{mso-style-name:aPart;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aSection, li.aSection, div.aSection
	{mso-style-name:aSection;
	mso-style-link:"aSection Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.75in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.aSP, li.aSP, div.aSP
	{mso-style-name:aSP;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;}
p.aSPComment, li.aSPComment, div.aSPComment
	{mso-style-name:aSPComment;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New \(W1\)";
	color:red;
	display:none;
	font-weight:bold;}
p.aSPFunds1, li.aSPFunds1, div.aSPFunds1
	{mso-style-name:aSPFunds1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aSPFunds2, li.aSPFunds2, div.aSPFunds2
	{mso-style-name:aSPFunds2;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aSPFundsHeading1, li.aSPFundsHeading1, div.aSPFundsHeading1
	{mso-style-name:aSPFundsHeading1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.aSPFundsHeading2, li.aSPFundsHeading2, div.aSPFundsHeading2
	{mso-style-name:aSPFundsHeading2;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.aSPHeading, li.aSPHeading, div.aSPHeading
	{mso-style-name:aSPHeading;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-1.0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.nonumber, li.nonumber, div.nonumber
	{mso-style-name:nonumber;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aSPHeadingLine, li.aSPHeadingLine, div.aSPHeadingLine
	{mso-style-name:aSPHeadingLine;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.ASPlist, li.ASPlist, div.ASPlist
	{mso-style-name:ASPlist;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.5in;
	margin-bottom:.0001pt;
	text-indent:-1.75in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aSPRequestedBY, li.aSPRequestedBY, div.aSPRequestedBY
	{mso-style-name:aSPRequestedBY;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New \(W1\)";}
p.aSPTitle, li.aSPTitle, div.aSPTitle
	{mso-style-name:aSPTitle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New \(W1\)";
	text-transform:uppercase;
	font-weight:bold;}
p.aSubChapter, li.aSubChapter, div.aSubChapter
	{mso-style-name:aSubChapter;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.aSubPart, li.aSubPart, div.aSubPart
	{mso-style-name:aSubPart;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.aTitle, li.aTitle, div.aTitle
	{mso-style-name:aTitle;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.cHistoryNote
	{mso-style-name:cHistoryNote;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Times New Roman",serif;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Times New Roman",serif;}
p.TOCPageHeader, li.TOCPageHeader, div.TOCPageHeader
	{mso-style-name:TOCPageHeader;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.aSPSubTitle, li.aSPSubTitle, div.aSPSubTitle
	{mso-style-name:aSPSubTitle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.aSPHeadingMiscellaneous, li.aSPHeadingMiscellaneous, div.aSPHeadingMiscellaneous
	{mso-style-name:aSPHeadingMiscellaneous;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-1.0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.aDistrict, li.aDistrict, div.aDistrict
	{mso-style-name:aDistrict;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.aBlock1Char
	{mso-style-name:"aBlock1 Char";
	mso-style-link:aBlock1;
	font-family:"Times New Roman",serif;}
span.aBlock2Char
	{mso-style-name:"aBlock2 Char";
	mso-style-link:aBlock2;
	font-family:"Times New Roman",serif;}
span.aBlock3Char
	{mso-style-name:"aBlock3 Char";
	mso-style-link:aBlock3;
	font-family:"Times New Roman",serif;}
span.aMargin1Char
	{mso-style-name:"aMargin1 Char";
	mso-style-link:aMargin1;
	font-family:"Times New Roman",serif;}
span.aSectionChar
	{mso-style-name:"aSection Char";
	mso-style-link:aSection;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.aBaseChar
	{mso-style-name:"aBase Char";
	mso-style-link:aBase;
	font-family:"Times New Roman",serif;}
span.aBillSectionChar
	{mso-style-name:"aBillSection Char";
	mso-style-link:aBillSection;
	font-family:"Times New Roman",serif;}
.MsoChpDefault
	{font-family:"Calibri",sans-serif;}
.MsoPapDefault
	{margin-bottom:10.0pt;
	line-height:115%;}
 /* Page Definitions */
 @page WordSection1
	{size:8.5in 11.0in;
	margin:.6in .9in .5in 1.2in;}
div.WordSection1
	{page:WordSection1;}
-->
</style>

</head>

<body lang=EN-US>

<div class=WordSection1>

<p class=nonumber align=center style='margin-top:24.0pt;text-align:center'><b>GENERAL
ASSEMBLY OF NORTH CAROLINA</b></p>

<p class=nonumber align=center style='margin-top:3.0pt;margin-right:0in;
margin-bottom:6.0pt;margin-left:0in;text-align:center'><b>SESSION 2019</b></p>

<p class=nonumber align=left style='text-align:left'><b>S                                                                                                                                                     1</b></p>

<p class=nonumber align=center style='text-align:center'><b>SENATE BILL 352</b></p>

<p class=nonumber align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=nonumber align=center style='text-align:center'><b>&nbsp;</b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=0
 style='width:6.55in;margin-left:-5.75pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=527 colspan=2 valign=top style='width:395.25pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in .05in 0in 5.4pt'>
  <p class=nonumber align=left style='margin-bottom:6.0pt;text-align:left'>Short
  Title:      Amend NC Controlled Substances Act.</p>
  </td>
  <td width=102 valign=top style='width:76.35pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in .05in 0in 5.4pt'>
  <p class=nonumber align=right style='margin-bottom:6.0pt;text-align:right'>(Public)</p>
  </td>
 </tr>
 <tr>
  <td width=96 valign=top style='width:71.85pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in .05in 0in 5.4pt'>
  <p class=nonumber align=left style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:left'>Sponsors:</p>
  </td>
  <td width=533 colspan=2 valign=top style='width:399.75pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in .05in 0in 5.4pt'>
  <p class=nonumber style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  3.0pt;margin-left:0in'>Senators McInnis and J. Davis (Primary Sponsors).</p>
  </td>
 </tr>
 <tr>
  <td width=96 valign=top style='width:71.85pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in .05in 0in 5.4pt'>
  <p class=nonumber align=left style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:3.0pt;margin-left:0in;text-align:left'>Referred to:</p>
  </td>
  <td width=533 colspan=2 valign=top style='width:399.75pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in .05in 0in 5.4pt'>
  <p class=nonumber style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  3.0pt;margin-left:0in'>Rules and Operations of the Senate</p>
  </td>
 </tr>
 <tr height=0>
  <td width=96 style='border:none'></td>
  <td width=431 style='border:none'></td>
  <td width=102 style='border:none'></td>
 </tr>
</table>

<p class=nonumber align=center style='margin-top:6.0pt;margin-right:0in;
margin-bottom:12.0pt;margin-left:0in;text-align:center'>March 26, 2019</p>

<p class=aBase align=center style='text-align:center'><span style='color:black'>A
BILL TO BE ENTITLED</span></p>

<p class=aLongTitle><span style='font-family:"Times New Roman",serif;
color:black'>AN ACT revising the north carolina controlled substances act.</span></p>

<p class=aBase><span style='color:black'>The General Assembly of North Carolina
enacts:</span></p>

<p class=aBillSection><b><span style='color:black'>SECTION 1.</span></b><span
style='color:black'>  G.S.&nbsp;90&#8209;87 reads as rewritten:</span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><span
style='color:black'>§ 90&#8209;87.  Definitions.</span></p>

<p class=aMargin1><span style='color:black'>As used in this Article:</span></p>

<p class=aBlock1><span style='color:black'>…</span></p>

<p class=aBlock1><span style='color:black'>(14a)    The term &quot;isomer&quot;
means <s>any type of isomer, including structural, geometric, or optical
isomers, and stereoisomers.</s><u>the optical isomer, unless otherwise
specified.</u></span></p>

<p class=aBlock1><span style='color:black'>…</span></p>

<p class=aBlock1><span style='color:black'>(17)      &quot;Narcotic drug&quot;
means any of the following, whether produced directly or indirectly by
extraction from substances of vegetable origin, or independently by means of
chemical synthesis, or by a combination of extraction and chemical synthesis:</span></p>

<p class=aBlock2><span style='color:black'>a.         Opium, opiate and opioid,
and any salt, compound, derivative, or preparation of opium, opiate, or opioid.</span></p>

<p class=aBlock2><span style='color:black'>b.         Any salt, compound,
isomer, derivative, or preparation thereof which is chemically equivalent or
identical with any of the substances referred to in clause a, but not including
the isoquinoline alkaloids of opium.</span></p>

<p class=aBlock2><span style='color:black'>c.         Opium poppy and poppy
straw.</span></p>

<p class=aBlock2><span style='color:black'>d.         Cocaine and any salt, <s>isomer,
</s><u>isomer (whether optical or geometric), </u>salts of isomers, compound,
derivative, or preparation thereof, or coca leaves and any salt, isomer, salts
of isomers, compound, derivative or preparation of coca leaves, or any salt,
isomer, salts of isomers, compound, derivative, or preparation thereof which is
chemically equivalent or identical with any of these substances, except that
the substances shall not include decocanized coca leaves or extraction of coca
leaves, which extractions do not contain cocaine or ecgonine.</span></p>

<p class=aBlock1><span style='color:black'>….&quot;</span></p>

<p class=aBillSection><b><span style='color:black'>SECTION 2.</span></b><span
style='color:black'>  G.S.&nbsp;90&#8209;89 reads as rewritten:</span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><span
style='color:black'>§ 90&#8209;89.  Schedule I controlled substances.</span></p>

<p class=aMargin1><span style='color:black'>This schedule includes the
controlled substances listed or to be listed by whatever official name, common
or usual name, chemical name, or trade name designated. In determining that a
substance comes within this schedule, the Commission shall find: a high potential
for abuse, no currently accepted medical use in the United States, or a lack of
accepted safety for use in treatment under medical supervision. The following
controlled substances are included in this schedule:</span></p>

<p class=aBlock1><span style='color:black'>(1)        Opiates. – Any of the
following opiates or opioids, including the isomers, esters, ethers, salts and
salts of isomers, esters, and ethers, unless specifically excepted, or listed
in another schedule, whenever the existence of such isomers, esters, ethers,
and salts is possible within the specific chemical designation:</span></p>

<p class=aBlock2><span style='color:black'>…</span></p>

<p class=aBlock2><span style='color:black'>hh.       Levophenacylmorphan.<u> For
purposes of this sub&#8209;subdivision only, the term &quot;isomer&quot;
includes the optical and geometric isomers.</u></span></p>

<p class=aBlock2><span style='color:black'>…</span></p>

<p class=aBlock2><u><span style='color:black'>mmm.</span></u><span
style='color:black'>  <u>3,4&#8209;dichloro&#8209;N&#8209;[2&#8209;(dimethylamino)cyclohexyl]&#8209;N&#8209;isopropylbenzamide
(also known as Isopropyl&#8209;U&#8209;47700).</u></span></p>

<p class=aBlock2><u><span style='color:black'>nnn.</span></u><span
style='color:black'>     <u>2&#8209;(3,4&#8209;dichlorophenyl)&#8209;N&#8209;[2&#8209;(dimethylamino)cyclohexyl]&#8209;N&#8209;methylacetamide
(also known as U&#8209;51754).</u></span></p>

<p class=aBlock2><u><span style='color:black'>ooo.</span></u><span
style='color:black'>     <u>2&#8209;(2,4&#8209;dichlorophenyl)&#8209;N&#8209;[2&#8209;(dimethylamino)cyclohexyl]&#8209;N&#8209;methylacetamide
(also known as U&#8209;48800).</u></span></p>

<p class=aBlock1><span style='color:black'>(1a)      Fentanyl derivatives. – <s>Any
compounds </s><u>Unless specifically excepted, listed in another schedule, or
contained within a pharmaceutical product approved by the United States Food
and Drug Administration, any compound </u>structurally derived from N&#8209;[1&#8209;(2&#8209;phenylethyl)&#8209;4&#8209;piperidinyl]&#8209;N&#8209;phenylpropanamide
(Fentanyl) by any substitution on or replacement of the phenethyl group, any
substitution on the piperidine ring, any substitution on or replacement of the
propanamide group, any substitution on the anilido phenyl group, or any
combination of the above unless specifically excepted or listed in another
schedule to include their salts, isomers, and salts of isomers. Fentanyl
derivatives include, but are not limited to, the following:</span></p>

<p class=aBlock2><span style='color:black'>…</span></p>

<p class=aBlock1><span style='color:black'>(2)        Opium derivatives. – Any
of the following opium derivatives, including their salts, <s>isomers, </s><u>isomers
(whether optical, positional, or geometric), </u>and salts of isomers, unless
specifically excepted, or listed in another schedule, whenever the existence of
such salts, isomers, and salts of isomers is possible within the specific
chemical designation:</span></p>

<p class=aBlock2><span style='color:black'>…</span></p>

<p class=aBlock1><span style='color:black'>(3)        Hallucinogenic
substances. – Any material, compound, mixture, or preparation which contains
any quantity of the following hallucinogenic substances, including their salts,
isomers, and salts of isomers, unless specifically excepted, or listed in
another schedule, whenever the existence of such salts, <s>isomers, </s><u>isomers
(whether optical, positional, or geometric), </u>and salts of isomers is
possible within the specific chemical designation:</span></p>

<p class=aBlock2><span style='color:black'>…</span></p>

<p class=aBlock2><u><span style='color:black'>nn.</span></u><span
style='color:black'>       <u>Substituted Tryptamines. – Any compound, unless
specifically excepted, specifically named in this schedule, or listed under a
different schedule, structurally derived from 2&#8209;(1H&#8209;indol&#8209;3&#8209;yl)ethanamine
(i.e., tryptamine) by mono&#8209; or di&#8209;substitution of the amine
nitrogen with alkyl or alkenyl groups or by inclusion of the amino nitrogen
atom in a cyclic structure whether or not the compound is further substituted
at the alpha position with an alkyl group or whether or not further substituted
on the indole ring to any extent with any alkyl, alkoxy, halo, hydroxyl, or
acetoxy groups. Substances in this class include, but are not limited to: 4&#8209;AcO&#8209;DiPT
(4&#8209;acetoxy&#8209;N,N&#8209;diisopropyltryptamine), 4&#8209;HO&#8209;MPMI
((R)&#8209;3&#8209;(N&#8209;methylpyrrolidin&#8209;2&#8209;ylmethyl)&#8209;4&#8209;hydoxyindole),
and DALT (N,N&#8209;diallyltryptamine).</u></span></p>

<p class=aBlock2><u><span style='color:black'>oo.</span></u><span
style='color:black'>       <u>Substituted Phenylcyclohexylamines. – Any
compound, unless specifically excepted or unless listed in another schedule, or
contained within a pharmaceutical product approved by the United States Food
and Drug Administration, any material, compound, mixture, or preparation
containing a phenylcyclohexylamine structure, with or without any substitution
on the phenyl ring, any substitution on the cyclohexyl ring, any replacement of
the phenyl ring with a thiophenyl or benzothiophenyl ring, with or without
substitution on the amine with alkyl, dialkyl, or alkoxy substituents,
inclusion of the nitrogen in a cyclic structure, or any combination of the
above. Substances in this class include, but are not limited to: BCP
(benocyclidine), PCMPA ((phenylcyclohexyl(methoxypropylamine)), and Hydroxy&#8209;PCP
((hydroxyphenyl)cyclohexylpiperidine).</u></span></p>

<p class=aBlock1><span style='color:black'>(4)        Systemic depressants. –
Any material compound, mixture, or preparation which contains any quantity of
the following substances having a depressant effect on the central nervous
system, including its salts, isomers, and salts of isomers whenever the
existence of such salts, isomers, and salts of isomers is possible within the
specific chemical designation, unless specifically excepted or unless listed in
another schedule:</span></p>

<p class=aBlock2><span style='color:black'>…</span></p>

<p class=aBlock2><u><span style='color:black'>g.</span></u><span
style='color:black'>         <u>Designer Benzodiazepines – Unless specifically
excepted or listed in another schedule, or contained within a pharmaceutical
product approved by the United States Food and Drug Administration, any
material, compound, derivative, mixture, or preparation, including its salts,
isomers, salts of isomers, halogen analogues, or homologues, whenever the
existence of such salts, isomers, or salts of isomers, halogen analogues, or
homologues is possible within the specific chemical designation, structurally
derived from 1,4&#8209;benzodiazepine by substitution at the 5&#8209;position
with a phenyl ring system (which may be further substituted), whether or not
the compound is further modified in any of the following ways:</u></span></p>

<p class=aBlock3><u><span style='color:black'>1.</span></u><span
style='color:black'>         <u>By substitution at the 2&#8209;position with a
ketone;</u></span></p>

<p class=aBlock3><u><span style='color:black'>2.</span></u><span
style='color:black'>         <u>By substitution at the 3&#8209;position with a
hydroxyl group or ester group, which itself may be further substituted;</u></span></p>

<p class=aBlock3><u><span style='color:black'>3.</span></u><span
style='color:black'>         <u>By a fused triazole ring at the 1,2&#8209;position,
which itself may be further substituted;</u></span></p>

<p class=aBlock3><u><span style='color:black'>4.</span></u><span
style='color:black'>         <u>By a fused imidazole ring at the 1,2&#8209;position,
which itself may be further substituted;</u></span></p>

<p class=aBlock3><u><span style='color:black'>5.</span></u><span
style='color:black'>         <u>By a fused oxazolidine ring at the 4,5&#8209;position,
which itself may be further substituted;</u></span></p>

<p class=aBlock3><u><span style='color:black'>6.</span></u><span
style='color:black'>         <u>By a fused oxazine ring at the 4,5&#8209;position,
which itself may be further substituted;</u></span></p>

<p class=aBlock3><u><span style='color:black'>7.</span></u><span
style='color:black'>         <u>By substitution at the 7&#8209;position with a
nitro group;</u></span></p>

<p class=aBlock3><u><span style='color:black'>8.</span></u><span
style='color:black'>         <u>By substitution at the 7&#8209;position with a
halogen group; or</u></span></p>

<p class=aBlock3><u><span style='color:black'>9.</span></u><span
style='color:black'>         <u>By substitution at the 1&#8209;position with an
alkyl group, which itself may be further substituted.</u></span></p>

<p class=aBlock1><span style='color:black'>(5)        Stimulants. – Unless
specifically excepted or unless listed in another schedule, any material,
compound, mixture, or preparation that contains any quantity of the following
substances having a stimulant effect on the central nervous system, including
its salts, isomers, and salts of isomers:</span></p>

<p class=aBlock2><span style='color:black'>…</span></p>

<p class=aBlock2><span style='color:black'>h.         4&#8209;methylmethcathinone
(also known as mephedrone).<u> For this compound, the term &quot;isomer&quot;
includes the optical, positional, or geometric isomer.</u></span></p>

<p class=aBlock2><span style='color:black'>i.          3,4&#8209;Methylenedioxypyrovalerone
(also known as MDPV).<u> For this compound, the term &quot;isomer&quot;
includes the optical, positional, or geometric isomer.</u></span></p>

<p class=aBlock2><span style='color:black'>j.          Substituted cathinones.
A compound, other than bupropion, that is structurally derived from 2&#8209;amino&#8209;1&#8209;phenyl&#8209;1&#8209;propanone
by modification in any of the following ways: (i) by substitution in the phenyl
ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl, or halide
substituents, whether or not further substituted in the phenyl ring by one or
more other univalent substituents; (ii) by substitution at the 3&#8209;position
to any extent; or (iii) by substitution at the nitrogen atom with alkyl,
dialkyl, benzyl, or methoxybenzyl groups or by inclusion of the nitrogen atom
in a cyclic structure.<u> For the purpose of this paragraph, the term &quot;isomer&quot;
includes the optical, positional, or geometric isomer.</u></span></p>

<p class=aBlock2><span style='color:black'>…</span></p>

<p class=aBlock1><span style='color:black'>(6)        NBOMe compounds. – Any
material compound, mixture, or preparation which contains any quantity of the
following substances, including its salts, <s>isomers, </s><u>isomers (whether
optical, positional, or geometric), </u>and salts of isomers whenever the
existence of such salts, isomers, and salts of isomers is possible within the
specific chemical designation unless specifically excepted or unless listed in
another schedule:</span></p>

<p class=aBlock2><span style='color:black'>…</span></p>

<p class=aBlock1><u><span style='color:black'>(8)</span></u><span
style='color:black'>        <u>Substituted Phenethylamines. – This includes any
compound, unless specifically excepted, specifically named or included in
another subset in this schedule, or listed under a different schedule,
structurally derived from phenylethan&#8209;2&#8209;amine by substitution on
the phenyl ring in any of the following ways, that is to say, by substitution
with a fused methylenedioxy ring, fused furan ring, or fused tetrahydrofuran
ring; by substitution with two alkoxy groups; by substitution with one alkoxy
and either one fused furan, tetrahydrofuran, or tetrahydropyran ring system; or
by substitution with two fused ring systems from any combination of the furan,
tetrahydrofuran, or tetrahydropyran ring systems. Whether or not the compound
is further modified in any of the following ways, that is to say: (i) by
substitution of phenyl ring by any halo, hydroxyl, alkyl, trifluoromethyl,
alkoxy, or alylthio groups; (ii) by substitution at the 2&#8209;position by any
alkyl groups; or (iii) by substitution at the 2&#8209;amino nitrogen atom with
alkyl, dialkyl, benzyl, hydroxybenzyl, methylenedioxybenzyl, or methoxybenzyl
groups. Substances in this class include, but are not limited to:  2C&#8209;I
(4&#8209;Iodo&#8209;2,5&#8209;dimethoxyphenethylamine), APDB ((2&#8209;aminopropyl)&#8209;2,3&#8209;dihydrobenzofuran),
MBDB (3,4&#8209;methylenedioxy&#8209;N&#8209;methylbutanamine), and 2C&#8209;I&#8209;NBOH
(N&#8209;(2&#8209;hydroxybenzyl)&#8209;4&#8209;iodo&#8209;2,5&#8209;dimethoxyphenethylamine).</u></span></p>

<p class=aBlock1><u><span style='color:black'>(9)</span></u><span
style='color:black'>        <u>N&#8209;Benzyl Phenethylamines. – Unless
specifically excepted or listed in another schedule, or contained within a
pharmaceutical product approved by the United States Food and Drug
Administration, any material, compound, mixture, or preparation, including its
salts, isomers (whether optical, geometric, or positional), esters, or ethers,
and salts of isomers, esters, or ethers, whenever the existence of such salts
is possible within any of the following specific chemical designations, any
compound containing a phenethylamine structure without a beta&#8209;keto group,
with substitution on the nitrogen atom of the amino group with a benzyl
substituent, with or without substitution on the phenyl or benzyl ring to any
extent with alkyl, alkoxy, thio, alkylthio, halide, fused alkylenedioxy, fused
furan, fused benzofuran, or fused tetrahydropyran substituents, whether or not
further substituted on a ring to any extent, with or without substitution at
the alpha position by any alkyl substituent. Substances in this class include,
but are not limited to: 25B&#8209;NBOH (4&#8209;bromo&#8209;2,5&#8209;dimethoxy&#8209;[N&#8209;(2&#8209;hydroxybenzyl)]phenethylamine),
25I&#8209;NBF (4&#8209;iodo&#8209;2,5&#8209;dimethoxy&#8209;[N&#8209;(2&#8209;fluorobenzyl)]phenethylamine),
and 25C&#8209;NBMD (4&#8209;chloro&#8209;2,5&#8209;dimethoxy&#8209;[N&#8209;(2,3&#8209;methylenedioxybenzyl)]phenethylamine).</u></span></p>

<p class=aBillSection><b><span style='color:black'>SECTION 3.</span></b><span
style='color:black'>  G.S.&nbsp;90&#8209;90(1) reads as rewritten:</span></p>

<p class=aBlock1><span style='color:black'>&quot;(1)      Any of the following
substances whether produced directly or indirectly by extraction from
substances of vegetable origin, or independently by means of chemical
synthesis, or by a combination of extraction and chemical synthesis, unless
specifically excepted or unless listed in another schedule:</span></p>

<p class=aBlock2><span style='color:black'>…</span></p>

<p class=aBlock2><span style='color:black'>d.         Cocaine and any salt, <s>isomer,</s>
<u>isomer (whether optical or geometric), </u>salts of isomers, compound,
derivative, or preparation thereof, or coca leaves and any salt, isomer, salts of
isomers, compound, derivative, or preparation of coca leaves, or any salt,
isomer, salts of isomers, compound, derivative, or preparation thereof which is
chemically equivalent or identical with any of these substances, except that
the substances shall not include decocanized coca leaves or extraction of coca
leaves, which extractions do not contain cocaine or ecgonine.</span></p>

<p class=aBlock2><span style='color:black'>….&quot;</span></p>

<p class=aBillSection><b><span style='color:black'>SECTION 4.</span></b><span
style='color:black'>  G.S.&nbsp;90&#8209;91(j) reads as rewritten:</span></p>

<p class=aMargin1><span style='color:black'>&quot;(j)       Any material,
compound, mixture, or preparation which contains any quantity of the following
substances having a stimulant effect on the central nervous system, including
its salts, <s>isomers, </s><u>isomers (whether optical, positional, or
geometric), </u>and salts of said isomers whenever the existence of such salts,
isomers, and salts of isomers is possible within the specific chemical
designation, unless specifically excluded or listed in some other schedule.</span></p>

<p class=aBlock1><span style='color:black'>1.         Benzphetamine.</span></p>

<p class=aBlock1><span style='color:black'>2.         Chlorphentermine.</span></p>

<p class=aBlock1><span style='color:black'>3.         Clortermine.</span></p>

<p class=aBlock1><span style='color:black'>4.         Repealed by Session Laws
1987, c. 412, s. 10.</span></p>

<p class=aBlock1><span style='color:black'>5.         Phendimetrazine.&quot;</span></p>

<p class=aBillSection><b><span style='color:black'>SECTION 5.</span></b><span
style='color:black'>  G.S.&nbsp;90&#8209;92(a) reads as rewritten:</span></p>

<p class=aSection><span style='color:black;font-weight:normal'>&quot;</span><span
style='color:black'>§ 90&#8209;92.  Schedule IV controlled substances.</span></p>

<p class=aMargin1><span style='color:black'>(a)        This schedule includes
the controlled substances listed or to be listed by whatever official name,
common or usual name, chemical name, or trade name designated. In determining
that a substance comes within this schedule, the Commission shall find: a low
potential for abuse relative to the substances listed in Schedule III of this
Article; currently accepted medical use in the United States; and limited
physical or pyschological dependence relative to the substances listed in
Schedule III of this Article. The following controlled substances are included
in this schedule:</span></p>

<p class=aBlock1><span style='color:black'>(1)        Depressants. – Unless
specifically excepted or unless listed in another schedule, any material,
compound, mixture, or preparation which contains any quantity of the following
substances, including its salts, isomers, and salts of isomers whenever the
existence of such salts, isomers, and salts of isomers is possible within the
specific chemical designation:</span></p>

<p class=aBlock2><span style='color:black'>…</span></p>

<p class=aBlock2><u><span style='color:black'>m1.</span></u><span
style='color:black'>      <u>Desalkylflurazepam.</u></span></p>

<p class=aBlock2><span style='color:black'>…</span></p>

<p class=aBlock2><u><span style='color:black'>n2.</span></u><span
style='color:black'>       <u>Diclazepam.</u></span></p>

<p class=aBlock2><span style='color:black'>…</span></p>

<p class=aBlock1><span style='color:black'>(2)        Any material, compound,
mixture, or preparation which contains any of the following substances,
including its salts, or isomers and salts of such isomers, whenever the
existence of such salts, isomers, and salts of isomers is possible:</span></p>

<p class=aBlock2><span style='color:black'>a.         Fenfluramine.<u> For this
compound, the term &quot;isomer&quot; includes the optical, positional, or
geometric isomer.</u></span></p>

<p class=aBlock2><span style='color:black'>b.         Pentazocine.</span></p>

<p class=aBlock1><span style='color:black'>….&quot;</span></p>

<p class=aBillSection><b><span style='color:black'>SECTION 6.</span></b><span
style='color:black'>  G.S.&nbsp;90&#8209;95(h)(3) reads as rewritten:</span></p>

<p class=aBlock1><span style='color:black'>&quot;(3)      Any person who sells,
manufactures, delivers, transports, or possesses 28 grams or more of cocaine
and any salt, <s>isomer, </s><u>isomer (whether optical or geometric), </u>salts
of isomers, compound, derivative, or preparation thereof, or any coca leaves
and any salt, isomer, salts of isomers, compound, derivative, or preparation of
coca leaves, and any salt, isomer, salts of isomers, compound, derivative or
preparation thereof which is chemically equivalent or identical with any of
these substances (except decocainized coca leaves or any extraction of coca
leaves which does not contain cocaine) or any mixture containing such
substances, shall be guilty of a felony, which felony shall be known as
&quot;trafficking in cocaine&quot; and if the quantity of such substance or
mixture involved:</span></p>

<p class=aBlock2><span style='color:black'>a.         Is 28 grams or more, but
less than 200 grams, such person shall be punished as a Class G felon and shall
be sentenced to a minimum term of 35 months and a maximum term of 51 months in
the State's prison and shall be fined not less than fifty thousand dollars
($50,000);</span></p>

<p class=aBlock2><span style='color:black'>b.         Is 200 grams or more, but
less than 400 grams, such person shall be punished as a Class F felon and shall
be sentenced to a minimum term of 70 months and a maximum term of 93 months in
the State's prison and shall be fined not less than one hundred thousand
dollars ($100,000);</span></p>

<p class=aBlock2><span style='color:black'>c.         Is 400 grams or more,
such person shall be punished as a Class D felon and shall be sentenced to a
minimum term of 175 months and a maximum term of 222 months in the State's
prison and shall be fined at least two hundred fifty thousand dollars
($250,000).&quot;</span></p>

<p class=aBillSection><b><span style='color:black'>SECTION 7.</span></b><span
style='color:black'>  This act becomes effective December 1, 2019, and applies
to offenses committed on or after that date.</span></p>

</div>

</body>

</html>
